Does pseudoangiomatous stromal hyperplasia increase a woman's risk of developing invasive breast cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pseudoangiomatous Stromal Hyperplasia Does NOT Increase Breast Cancer Risk

Pseudoangiomatous stromal hyperplasia (PASH) is classified as a nonproliferative benign breast lesion that does not confer increased risk for developing invasive breast cancer, and women with PASH should follow standard average-risk screening guidelines. 1

Evidence-Based Risk Classification

The ACR Appropriateness Criteria (2022) explicitly categorizes benign breast disease into three groups based on cancer risk 1:

  • Nonproliferative lesions (no increased risk): fibrocystic changes, fibroadenomas, lipomas, fat necrosis, nonsclerosing adenosis
  • Proliferative lesions without atypia (minimal increased risk): usual ductal hyperplasia, sclerosing adenosis, complex fibroadenomas, radial scars, papillomas
  • Proliferative lesions with atypia (significantly increased risk): atypical ductal hyperplasia, atypical lobular hyperplasia, LCIS, flat epithelial atypia

PASH is notably absent from all three categories because it is a stromal (not epithelial) proliferative process and does not represent a precursor lesion or risk factor for breast cancer.

Direct Research Evidence

The most definitive study addressing this question is a large single-institution cohort study that followed 9,065 women who underwent benign breast biopsy over 18.5 years 2. Key findings:

  • PASH was identified in 579 biopsies (6.4%)
  • Women with PASH had lower breast cancer risk (SIR 1.03,95% CI 0.71-1.44) compared to women without PASH (SIR 1.54,95% CI 1.43-1.65), P = 0.01
  • Only 5.9% of women with PASH developed subsequent breast cancer versus 8.8% without PASH
  • This lower risk persisted across all subgroups stratified by age, family history, epithelial proliferation, and involution

Multiple contemporary studies confirm these findings 3, 4:

  • A 2023 study with mean follow-up of 55 months found no malignant transformation in any PASH patients 3
  • A 2026 study of 185 patients with median 6.2-year follow-up found subsequent breast atypia or carcinoma was uncommon (5.4%), consistent with average population risk 4

Clinical Management Algorithm

For women diagnosed with PASH:

  1. Screening approach: Follow standard average-risk guidelines

    • Annual mammography starting at age 40 1
    • No need for enhanced surveillance, MRI, or shortened intervals
    • No need for earlier screening before age 40 unless other risk factors present
  2. Treatment decisions: Based on symptoms, not cancer risk

    • Asymptomatic/incidental PASH: Observation is appropriate 3, 5
    • Symptomatic or large masses: Surgical excision with clean margins for symptom relief 3, 6, 5
    • Surgery is for diagnostic certainty or symptom management, not cancer prevention
  3. Follow-up: Standard clinical breast examination and age-appropriate screening

    • No special surveillance protocols required
    • Recurrence after excision is uncommon (5 of 40 patients in one series) 7

Important Clinical Distinctions

Do not confuse PASH with high-risk proliferative lesions:

  • Atypical ductal hyperplasia confers 4-5 fold increased risk 8
  • LCIS confers 6-10 fold increased risk 8
  • These lesions warrant enhanced screening with possible MRI 1, 8

PASH is a stromal myofibroblastic proliferation (CD34+, hormone receptor variable) that creates pseudovascular spaces but involves no epithelial atypia 7, 4. The frequent association with fat necrosis (93.8%) and fibrocystic changes (88.1%) suggests a chronic, hormone-related benign process rather than a premalignant condition 4.

Common Clinical Pitfalls

  • Imaging mimicry: PASH can present as a palpable mass clinically resembling fibroadenoma or even phyllodes tumor, particularly in younger women 7, 6, 9
  • Overtreatment: The presence of PASH should not trigger enhanced surveillance or risk-reduction strategies
  • Misclassification: Ensure pathology confirms PASH and excludes proliferative lesions with atypia, which do increase cancer risk

The clinical concern generated by palpable density associated with PASH should not be mistaken for increased malignancy risk 2. Women with PASH require reassurance that their breast cancer risk remains at population baseline.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.